Cambridge, MA-based Idenix Pharmaceuticals has earned a hefty $20 million milestone based on ViiV Healthcare's progress with an experimental HIV/AIDS program. "We are pleased with the continued progress of '761 and the initiation of a Phase IIb clinical trial in HIV-infected patients," said Ronald Renaud, president and chief executive officer of Idenix. "We look forward to the continued progress of this program." Idenix release